VivoSim Labs (VIVS) Cash & Equivalents (2010 - 2026)

VivoSim Labs has reported Cash & Equivalents for 17 years, with the latest figure at $1.7 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 81.23% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 81.23% decrease from a year earlier, with the FY2026 full-year figure at $5.0 million, down 55.59% from the prior year.
• Cash & Equivalents was $1.7 million for Q2 2026 at VivoSim Labs, down from $5.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $28.7 million in Q1 2022, with the low at $1.2 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $9.3 million, with a median of $7.2 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 289.93% in 2025, then tumbled 81.23% in 2026.
• Over 5 years, Cash & Equivalents stood at $20.2 million in 2022, then slumped by 73.78% to $5.3 million in 2023, then tumbled by 78.07% to $1.2 million in 2024, then surged by 270.37% to $4.3 million in 2025, then plunged by 60.47% to $1.7 million in 2026.
• The last three Cash & Equivalents figures came in at $1.7 million (Q2 2026), $5.0 million (Q1 2026), and $4.3 million (Q4 2025), per Business Quant data.